Familial prevalence of autoimmune disorders in multiple sclerosis in Northern Greece

Abstract

Objective: The objective of this study was to evaluate for up to 7 years the prevalence of autoimmune disorders among naïve (untreated) multiple sclerosis family members compared with a contemporary general control population in Northern Greece, in a prospective case-control study, and to examine the possible relationship between immunomodulatory treatment and the appearance of additional autoimmune disorders.

Methods: The patients and controls enrolled comprised 1383 patients with definite MS and 4392 relatives in their families and a total of 452 controls families with 1652 members.

Results: At baseline, 891 multiple sclerosis families with 3112 members (73 multiplex multiple sclerosis families with 292 members and 818 simplex families with 2820 members) and 355 control families with 1580 members were examined regarding whether they had any of 12 autoimmune diseases. The baseline affected multiplex plus simplex multiple sclerosis families, the family members and the coexistent additional autoimmune disorders were higher compared with controls. There was an increase in longitudinally affected multiple sclerosis families, multiple sclerosis family members and coexistent additional autoimmune disorders compared with respective findings at the baseline observation. Comparison analysis between two time point observations (after a mean 7.1 ± 2.2 years) for each autoimmune disorder in overall multiple sclerosis family members revealed increased rates for longitudinal autoimmune Hashimoto’s thyroiditis, Graves’ disease, insulin-dependent diabetes mellitus, psoriasis and vitiligo (p = 0.02, p = 0.006, p = 0.0004, p = 0.05, and p = 0.05, respectively). Some 145 newly developed, longitudinally definite autoimmune cases were recognized in multiplex plus simplex multiple sclerosis families; 116 (80%) of these disorders were observed in patients with multiple sclerosis treated with immunomodulatory medications, and 68 of these 116 (58.6%) cases exhibited baseline positive autoreactive antibodies. Binary logistic regression analysis revealed that immunotherapy predisposes to autoimmunity (odds ratio 2.8, p < 0.001) independently of the presence of baseline autoantibodies and patients’ gender.

Conclusions: There is a longitudinally increased frequency of additional autoimmune disorders among multiple sclerosis family members, probably related to immunomodulatory therapy.

Keywords

multiple sclerosis familial prevalence autoimmunity T lymphocytes immunomodulation interferon beta

Get full access to this article

View all access options for this article.

References

Kasper LH and Shoemaker J. Multiple sclerosis immunology: The healthy immune system vs the MS immune system. Neurology 2010; 74(Suppl 1): S2-S8.

McFarland HF and Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol 2007; 8: 913-919.

Sadovnick AD European Charcot Foundation Lecture: the natural history of multiple sclerosis and gender. J Neurol Sci 2009; 286: 1-5.

Vukusic S. , Hutchinson M. , Hours M. , Moreau T. , Cortinovis-Tourniaire P. , Adeleine P. , et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004 ; 127: 1353-1360.

Lassmann H. Models of multiple sclerosis: new insights into pathophysiology and repair . Curr Opin Neurol 2008; 21: 242-247.

Weiner HL The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009; 65: 239-248.

Nielsen NM , Westergaard T. , Frisch M. , Rostgaard K. , Wohlfahrt J. , Koch-Henriksen N. , et al. Type 1 diabetes and multiple sclerosis: A Danish population-based cohort study. Arch Neurol 2006; 63: 1001-1004.

Sloka JS , Phillips PW , Stefanelli M. and Joyce C. Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort . J Autoimmune Dis 2005; 9: 2-9.

Annunziata P. , Morana P. , Giorgio A. , Galeazzi M. , Campanella V. , Lore F. , et al. High frequency of psoriasis in relatives is associated with early onset in an Italian multiple sclerosis cohort. Acta Neurol Scand 2003 ; 108: 327-331.

10.

Cohen R. , Robinson Jr D. , Paramore C. , Fraeman K. , Renahan K. and Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis 2008; 14: 738-743.

11.

Barcellos LF , Kamdar BB , Ramsay PP , DeLoa C. , Lincoln RR , Caillier S. , et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol 2006; 5: 924-931.

12.

Henderson RD , Bain CJ and Pender MP The occurrence of autoimmune diseases in patients with multiple sclerosis and their families . J Clin Neurosci 2000; 7: 434-437.

13.

Heinzlef O. , Alamowitch S. , Sazdovitch V. , Chillet P. , Joutel A. , Tournier-Lasserve E. , et al. Autoimmune diseases in families of French patients with multiple sclerosis . Acta Neurol Scand 2000; 101: 36-40.

14.

Broadley SA , Deans J. , Sawcer SJ , Clayton D. and Compston DA Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 2000; 123: 1102-1111.

15.

Nielsen NM , Frisch M. , Rostgaard K. , Wohlfahrt J. , Hjalgrim H. , Koch-Henriksen N. , et al. Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler 2008; 14: 823-829.

16.

Laufer TM and Wu GF Treating MS : getting to know the two birds in the bush . J Clin Invest 2009; 119: 2852-2853.

17.

McDonald WI , Compston A. , Edan G. , Goodkin D. , Hartung HP , Lublin FD , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-127.

18.

Somers EC , Thomas SL , Smeeth L. and Hall AJ

Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder?

Am J Epidemiol 2009; 169: 749-755.

19.

Cooper GS , Bynum ML and Somers EC Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009; 3: 197-207.

20.

Sawcer S. , Ban M. , Wason J. and Dudbridge F.

What role for genetics in the prediction of multiple sclerosis?

Ann Neurol 2010; 67: 3-10.

21.

Hewagama A. and Richardson B. The genetics and epigenetics of autoimmune diseases. J Autoimmun 2009; 33: 3-11.

22.

Gavalas E. , Kountouras J. , Deretzi G. , Boziki M. , Grigoriadis N. , Zavos C. , et al. Helicobacter pylori and multiple sclerosis. J Neuroimmunol 2007; 188: 187-189.

23.

Deretzi G. , Kountouras J. , Grigoriadis N. , Zavos C. , Chatzigeorgiou S. , Koutlas E. , et al. From the ‘‘little brain’’ gastrointestinal infection to the ‘‘big brain’’ neuroinflammation: a proposed fast axonal transport pathway involved in multiple sclerosis. Med Hypotheses 2009; 73: 781-787.

24.

Burdick LM , Somani N and Somani AK. Type I IFNs and their role in the development of autoimmune diseases. Expert Opin Drug Saf 2009; 8: 459-472.

25.

Garg N. , Zivadinov R. , Ramanathan M. , Vasiliu I. , Locke J. , Watts K. , et al. Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol 2007; 187: 159-165.

26.

Eggert M. , Zettl UK and Neeck G. Autoantibodies in autoimmune diseases. Curr Pharm Des 2010; 16: 1634-1643.

27.

Caraccio N. , Cuccato S. , Pratesi F. , Dardano A. , Ursino S. , Chimenti D. , et al. Effect of type I interferon(s) on cell viability and apoptosis in primary human thymocyte cultures. Thyroid 2009; 19: 149-155.

28.

Durelli L. , Oggero A. , Verdun E. , Isoardo GL , Barbero P. , Bergamasco B. , et al. Betaferon Safety Trial Study Group. Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab 2001; 86: 3525-3532.

29.

Polman CH , Kappos L. , Dahlke F. , Graf R. , Beckmann K. , Bogumil T. , et al. European Study Group on Interferon Beta-1b in SPMS. Interferon beta-1b treatment does not induce autoantibodies. Neurology 2005; 64: 996-1000.

30.

Coles AJ , Wing M. , Smith S. , Coraddu F. , Greer S. , Taylor C. , et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999 ; 354: 1691-1695.

31.

CAMMS223 Trial Investigators , Coles AJ , Compston DA , Selmaj KW , Lake SL , Moran S. , Margolin DH , et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis . N Engl J Med 2008; 359: 1786-1801.

32.

Lo-Pez-Lerma I. , Pranzo P. and Herreo C. New-onset psoriasis in a patient treated with interferon beta-1a. Br J Dermatol 2009; 160: 716-717.

33.

Fromont A. , De Seze J. , Fleury MC , Maillefert JF and Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009; 45: 55-72.

34.

Kocer B. , Nazliel B. , Oztas M. and Batur HZ Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report. Eur J Neurol 2009; 16: 78-79.

35.

Schott E. , Paul F. , Wuerfel JT , Zipp F. , Rudolph B. , Wiedenmann B. , et al. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a. World J Gastroenterol 2007; 13: 3638-3640.

36.

Charach G. , Grosskopf I. and Weintraub M. Development of Crohn’s disease in a patient with multiple sclerosis treated with copaxone. Digestion 2008; 77: 198-200.